pixuvri Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Pixantrone is an experimental antineoplastic (anti-cancer) drug, an analogue of mitoxantrone with fewer toxic effects on cardiac tissue. It acts as a topoisomerase II poison and intercalating agent. The code name BBR 2778 refers to pixantrone dimaleate, the actual substance commonly used in clinical trials.   Wikipedia

Chemistry

  • SMILES: NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12
  • InChIKey: PEZPMAYDXJQYRV-UHFFFAOYSA-N
  • Mol. Mass: 325.37
  • ALogP: 0.6
  • ChEMBL Molecules:
    pixantrone  
    pixantrone dimaleate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

5,8-bis((2-aminoethyl)amino)-2-aza-anthracene-9,10-dione | 5,8-bis(2-aminoethylamino)-2-azaanthracene-9,10-dione | 6,9-aea-biqdo | 6,9-bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione | bbr2778 | bbr 2778 | bbr-2778 | pix | pixantrone | pixantrone dimaleate | pixantrone maleate | pixuvri

Organizations (16)

Research & Development (16)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Breast Neoplasms (Phase 2)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Myeloid, Acute (Phase 1/Phase 2)

Lymphoma (Phase 3)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Large-Cell, Immunoblastic (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Neoplasms ()

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial Organizations: 16

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue